Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Anne Peters, MD
Advertisement
Articles by Anne Peters, MD
Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.
Advertisement
Latest Updated Articles
- Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
Published: September 20th 2016 | Updated:
- Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Published: February 12th 2013 | Updated:
- Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
Published: July 2nd 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
2
Physical Activity, Vaccination May Protect Against Long COVID
3
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
4
mRNA COVID-19 Vaccines Not Associated With Major Congenital Malformations During Pregnancy
5
